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Abstract
The mouse is a valuable model for unravelling the role of hepcidin in iron homeostasis, however, such studies still report
hepcidin mRNA levels as a surrogate marker for bioactive hepcidin in its pivotal function to block ferroportin-mediated iron
transport. Here, we aimed to assess bioactive mouse Hepcidin-1 (Hep-1) and its paralogue Hepcidin-2 (Hep-2) at the peptide
level. To this purpose, fourier transform ion cyclotron resonance (FTICR) and tandem-MS was used for hepcidin
identification, after which a time-of-flight (TOF) MS-based methodology was exploited to routinely determine Hep-1 and -2
levels in mouse serum and urine. This method was biologically validated by hepcidin assessment in: i) 3 mouse strains
(C57Bl/6; DBA/2 and BABL/c) upon stimulation with intravenous iron and LPS, ii) homozygous Hfe knock out, homozygous
transferrin receptor 2 (Y245X) mutated mice and double affected mice, and iii) mice treated with a sublethal hepatotoxic
dose of paracetamol. The results showed that detection of Hep-1 was restricted to serum, whereas Hep-2 and its presumed
isoforms were predominantly present in urine. Elevations in serum Hep-1 and urine Hep-2 upon intravenous iron or LPS
were only moderate and varied considerably between mouse strains. Serum Hep-1 was decreased in all three
hemochromatosis models, being lowest in the double affected mice. Serum Hep-1 levels correlated with liver hepcidin-1
gene expression, while acute liver damage by paracetamol depleted Hep-1 from serum. Furthermore, serum Hep-1
appeared to be an excellent indicator of splenic iron accumulation. In conclusion, Hep-1 and Hep-2 peptide responses in
experimental mouse agree with the known biology of hepcidin mRNA regulators, and their measurement can now be
implemented in experimental mouse models to provide novel insights in post-transcriptional regulation, hepcidin function,
and kinetics.
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Introduction
The control of iron homeostasis acts at both the cellular and
the systemic level and involves a complex system of different cell
types, transporters and signals. To maintain systemic iron
homeostasis, communication between cells that absorb iron
from the diet (duodenal enterocytes), consume iron (mainly
erythroid precursors) and store iron (hepatocyte and tissue
macrophages) must be tightly regulated. The recently identified
b-defensin-like anti-microbial peptide hepcidin is thought to be
the long anticipated regulator that controls iron absorption and
macrophage iron release. It is synthesized in the liver upon
changes in body iron stores, anemia, hypoxia and inflammation,
and secreted in the circulation [1]. Hepcidin is reported to
counteract the function of ferroportin, a major cellular iron
exporter protein in the membrane of macrophages and the
basolateral site of enterocytes, by inducing its internalization and
degradation [2].
Much of the data concerning the involvement of hepcidin in
iron metabolism were initially generated in mouse models.
Whereas humans, rats, pigs and dogs have a single gene, due to
gene duplications there are 2 hepcidin genes in mice, i.e. hepcidin-1
and hepcidin-2 [2,3]. These two genes are located in the same
region on mouse chromosome 7. While hepcidin-1 is almost
exclusively expressed in the liver, hepcidin-2 is also expressed in the
pancreas [4,5].
At the functional level both hepcidin genes are upregulated in iron
loaded mice [5]. Induction of inflammation increased hepcidin-1 [6],
but repressed hepcidin-2 in the liver [4,7]. Targeted disruption of the
hepcidin-1 gene has been shown to result in severe tissue iron overload
[8], whereas mice overexpressing hepcidin-1 develop iron deficiency
anemia [6]. However, mice overexpressing hepcidin-2 presented with
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1 (Hep-1) peptide is able to regulate iron homeostasis and highlights
the non-redundant roles of Hep-1 and Hep-2 in mice and points
toward divergent functions of both peptides. The evolutionary
advantage of having two hepcidin proteins is, however, still unknown.
Both peptides are 68% identical and contain 8 cysteine residues,
which form 4 intra-molecular disulfide bridges in the 25-amino-
acid (aa) mature peptide (predicted structures are shown in Figure
S1). While Hep-1 is most similar to human Hepcidin-25, which
has a proven role in iron metabolism, Hep-2 shares some common
features with fish hepcidin-like peptides and therefore might share
common functions with the latter peptides, possibly in innate
immunity [9,10].
As the mouse has been shown to be a valuable model to unravel
iron metabolism disorders, the current study aimed at the
development of a methodology to measure mouse hepcidin on
the peptide level by mass spectrometry. For reasons of compre-
hensiveness, we aimed at the analysis of both Hep-1 and Hep-2 in
mouse serum and urine samples, despite the fact that the exact
function of the latter peptide (if any), needs to be elucidated.
Results
Identification of serum Hep-1 and urine Hep-2
IMAC-Cu
2+ on-chip chemistry was used to enrich hepcidin
peptides from mouse serum and urine after which peptides were
visualized by TOF MS. A serum-derived peak with measured
mass of m/z 2754 matched to the synthetic Hep-1 reference
peptide, whereas an urine-born peak with m/z 2821 corresponded
to the theoretical mass of Hep-2 (Figure 1). Upon chemical
reduction, the presumed Hep-1 and Hep-2 peaks displayed a mass
shift of 8 Da, which is diagnostic of 4 disulfide bridges in the
parental peptides (Figures S2 and S3) [11]. Conclusively, tandem
MS analysis on a mouse urine sample as performed previously for
human urine hepcidin [12,13] showed that the suspected Hep-2
peak indeed matched with the deduced amino acid sequence of
the hepcidin-2 gene (Figure S4). For the identification of Hep-1 an
accurate mass measurement using MALDI-FTICR MS in
combination with a bioinformatics approach was employed.
Searches in the mouse protein database resulted in 6 possible
peptides containing 8 cysteine residues within a mass tolerance
window of 650 ppm from Hep-1 (Table S1). External calibration
of the MALDI-FTICR spectrum (Figure S5) resulted in a
monoisotopic mass measurement of m/z 2753.032 with a standard
deviation of 62.5 ppm. From this it was deduced that only the
masses of Hep-1 and a 28 aa internal peptide from metallothio-
nein-1 fitted within three standard deviations (.99.7% confidence)
of the measured mass of this peak. Interestingly, further
investigation of the MALDI-FTICR spectrum showed a mono-
isotopic signal at m/z 2637.989 that could be derived from an in-
source peptide fragmentation event. This was evident from the
isotopic distributions of the signals at 2753 and 2637 that were
Figure 1. IMAC-Cu
2+ TOF MS analysis of mouse Hepcidin. A. Synthetic mouse Hep-1 peptide; B. Serum from a C57Bl/6 mouse and C. urine
from a FVB mouse (C) spiked with Hepcidin-24 [13] as internal standard (IS). Positions of Hep-1, Hep-2 and IS are indicated. Peak intensity is given in
arbitrary units (AU).
doi:10.1371/journal.pone.0016762.g001
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mass difference, the m/z 2637.989 signal could only be assigned to
the Hep-1 peptide lacking the N-terminal aspartic acid (D) residue
(Figure S5). From these combined analyses it was concluded that
the employed on-chip chemistry is an convenient approach to
detect mouse hepcidin peptides.
Hep-1 and -2 peptide levels in serum and urine from
different mouse strains
The broad applicability of the IMAC-Cu
2+ TOF MS procedure
was illustrated by the detection of Hep-1/-2 peptides in serum and
urine from FVB, DBA/2, C57Bl/6 and BALB/c mice (see
Figures 1 and S6), Hep-1 appeared to be the dominant hepcidin
form in serum, whereas Hep-2 was dominant in urine. Notably,
Hep-1 and -2 from DBA/2 mice have a different mass due to
asparagine to lysine (Hep-1) and serine to phenylalanine (Hep-2)
substitutions at positions 16 and 18 as compared to the respective
mature hepcidin peptides (see Figure S1). The observed deviate
masses of Hep-1 (m/z 2768) and Hep-2 (m/z 2881) of DBA mice
match to their altered aa composition. Similar to humans, a
presumed amino-terminally truncated 20 aa isoform of Hep-2 was
detected in urine of all mouse strains, whereas possible 22 aa and
23 aa isoforms of Hep-2 were detected in urine from C57Bl/6 and
DBA/2 mice. Isoform levels appeared highest for DBA/2 mouse
(Figure S7), however, it should be realized that no MS/MS
confirmation of the identity of these Hep-2 isoforms was obtained.
Together, these experiments show that Hep-1 and Hep-2 (and
possible isoforms) can be accurately detected in serum and urine
from different mouse strains.
Serum Hep-1 is predominantly produced by the liver
To further gain in vivo evidence that Hep-1 is a liver-produced
peptide, FVB mice were treated with a sub-lethal dose of
paracetamol to induce acute liver damage. This clearly showed
that after 24 hrs, serum Hep-1 significantly decreased (Figure 2),
whereas serum ALAT levels significantly increased from mean 52
U/L (SD 17) in controls to a mean of 11188 U/L (SD 11823) in
treated mouse. The latter is diagnostic for severe liver damage. In
contrast, urine Hep-2 levels (collected until 24 hours after start of
treatment) remained essentially unaffected during treatment which
is suggestive for expression in other organs (data not shown).
Correlation of serum Hep-1 with liver hepcidin-1 mRNA
and liver/spleen iron content
As the current study provides a new tool to directly evaluate
bioactive Hep-1 levels in the circulation, we aimed to assess the
correlation between Hep-1 and liver hepcidin-1 gene expression.
We also included spleen iron levels in the correlations to assess
whether hepcidin induced iron withholding by the reticulo-
endothelial macrophages. Therefore, serum, spleen and liver
tissue from control mouse and hemochromatosis mouse models
were collected for parallel analysis of these parameters. As shown
in Figure 3, serum Hep-1 levels correlated significantly with liver
hepcidin-1 mRNA levels (r=0.8263,p,0.001). Interestingly, serum
Hep-1 levels showed to be an excellent determinant for spleen iron
levels (Figure 4A). Furthermore, liver iron levels, but not serum
iron concentrations, significantly correlated with serum Hep-1
levels (Figure 4B and C).
Hepcidin levels in hemochromatosis mouse models
To evaluate the functional importance of measured Hep-1 and
Hep-2 levels in various genetic variants of hemochromatosis,
serum was collected from wild-type mice (wt), Hfe KO, Tfr2
y245x
or Hfe/TfR2
y245x mouse. These analyses showed that Hep-2 levels
in serum were below the lower limit of detection. As shown in
Figure 5, liver hepcidin-1 mRNA levels (panel A) as well as serum
Hep-1 levels (panel B) were decreased in all three hemochroma-
tosis models and lowest in the double affected Hfe/TfR2
y245x mice.
Hep-1 and Hep-2 levels upon challenge with iron and
LPS
To investigate the responses of mouse hepcidin to iron and
inflammatory stimuli, intravenous iron and LPS were adminis-
Figure 2. Serum Hep-1 levels in control FVB mice (n=5) and
mice 24 hrs after i.p. treatment with a sublethal hepatotoxic
dose of 350 mg paracetamol/kg bw (n=4). Data are depicted as
lower quartile, median and upper quartile (boxes), and minimum and
maximum ranges (whiskers). *Differences between control and treated
mice tested by (two tailed) Mann-Whitney test (P,0.05).
doi:10.1371/journal.pone.0016762.g002
Figure 3. Correlation between serum Hep-1 and liver hepcidin-1
mRNA. Data are obtained from wild type mice (n=8), Hfe knockout
mice (n=3), TfR2
Y245X mice and double affected Hfe/TfR2
Y245X mice
(n=4). Real time values are expressed as mRNA content relative to the
mean value obtained for the wild-type mice. Likewise serum Hep-1
values are expressed relative to the mean value from the wild type
mice. r (Spearman)=0.8263, P,0.001.
doi:10.1371/journal.pone.0016762.g003
Hepcidin in Mouse Models
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experiments. In the first experiment, serum Hep-1 and urine Hep-
2 were measured 24 hours after iron and LPS stimulus in three
different mouse strains. As shown in Figure 6A, serum Hep-1
elevations to both iron and LPS administration were significant in
DBA/2 mice and C57Bl/6, but not in BALB/c. Moreover,
baseline Hep-2 levels in urine from DBA/2 mice were several
magnitudes of units higher than those of the other two mouse
strains (Figure 6B). LPS administration had no effect on Hep-2
levels in the urine of C57Bl/6 and BALB/c mice, but significantly
decreased urine Hep-2 levels in DBA/2. Iron administration
significantly increased Hep-2 levels in C57Bl/6 mice, whereas no
effect on Hep-2 levels in urine from BALB/c and DBA/2 mice
was observed. It should be mentioned, however, that differences
with DBA/2 control mice may have been missed due to restricted
urine sample volume which precluded more precise assessment of
the Hep-2 levels. To examine the time course of Hep-1 induction
upon inflammation in more detail, C57Bl/6 mice were injected
with LPS in a second experiment. Serum Hep-1 levels were
measured during a 6 hrs time course along with IL-6 levels as a
marker for the inflammatory response. As shown in Figure 7, both
IL-6 and Hep-1 levels significantly increased in time with a peak
expression after about 4 hrs, similar to what has been observed in
humans [12]. Altogether these experiments show that Hep-1 and
Hep-2 are differently regulated by LPS and iron, whereas this
regulation itself is dependent on the genetic background of the
mouse strain.
Discussion
The mouse is a valuable model for understanding human iron
disorders. Markedly, mouse studies still report hepcidin mRNA
levels as a surrogate marker for bioactive hepcidin in its pivotal
function to block ferroportin-mediated iron transport. Unlike
humans, mice contain two related hepcidin genes of which only
hepcidin-1 seems to be important for iron homeostasis and is
primarily expressed in the liver. Instead. the hepcidin-2 gene is
predominantly expressed in the pancreas in some, but not all, mice
strains [5,7]. Here, we developed a methodology to investigate
production and fate of both Hep-1 and -2 peptides in various
mouse models for iron metabolism disorders.
We found serum Hep-1 levels in C57Bl/6 mice to be increased
upon LPS administration in parallel with serum IL-6 levels, which
is consistent with a previous report on liver and pancreas hepcidin-1
expression [7]. Furthermore, we found serum Hep-1 levels to be
increased both upon iron and LPS administration in all 3
investigated mice strains (C57Bl/6 and DBA/2 and BALB/c).
Similar increases in liver hepcidin-1 mRNA levels upon both stimuli
were previously reported, while pancreas hepcidin-1 expression only
increased upon LPS administration [7,14]. Thus, our mass
spectrometry data show that serum Hep-1 represents an
convenient marker in mouse models of inflammation and iron
overload. The fact that serum Hep-1 levels correlated with liver
hepcidin-1 expression and disappeared upon acute liver damage by
paracetamol intoxication implies that the liver is indeed the
Figure 4. Correlations between serum Hep-1 and liver hepcidin-1 mRNA, and iron concentrations of serum, spleen and liver. Data are
obtained from wild type mice (n=8), Hfe knockout mice (n=3), TfR2
Y245X mice and double affected Hfe/TfR2
Y245X mice (n=4). Correlation was
tested by Spearman. ns, not significantly different.
doi:10.1371/journal.pone.0016762.g004
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seemed to be modest, especially for LPS compared to Hepcidin-25
responses during human endotoxemia [15]. The latter emphasizes
that results from mouse models cannot directly be translated to
human iron metabolism.
In contrast to serum Hep-1, the origin of urine Hep-2 remains
elusive. We showed that baseline urine Hep-2 levels of DBA/2
mice were substantially higher than that of the other mouse strains
and that i.v. iron administration significantly increased urine Hep-
2 levels in C57Bl/6 mice, which is in agreement with previous
reports on mouse liver hepcidin-2 expression [7,14]. Conversely,
pancreas hepcidin-2 expression was previously reported to be most
highly expressed in C57Bl/6 mice [7], while i.v. iron administra-
tion did not increase mouse pancreas hepcidin-2 mRNA levels.
Furthermore, our current data show that LPS challenge did not
raise Hep-2 levels in the urine of C57Bl/6 mice, while these levels
in DBA/2 were decreased. Although, the above observations
could suggest that the contribution of the liver to urine Hep-2
levels is superior to that of the pancreas, not all observations can
be explained by this assumption. First, Krijt et al. [7] showed that
only pancreatic hepcidin-2 expression was decreased upon LPS
administration in C57Bl/6 and DBA/2 mice. Second, we did not
observe a significant increase of urine Hep-2 levels in BALB/c
mice, whereas oral iron loading in BALB/c mice was previously
shown to result in a clear hepcidin-2 expression increases in both
liver and pancreas [5]. Third, we did not obtain evidence that
urine Hep-2 levels were affected by hepatotoxic paracetamol
dosage. Accordingly, the latter findings are in-line with the idea
that urine Hep-2 does not primarily originate from the liver. Thus
based on the current state-of-the-art, we tend to believe that
neither the pancreas nor the liver is the major source of urine Hep-
2. Unfortunately, apart from the liver we did not harvest RNA
from other mouse organs to co-investigate hepcidin-2 expression in
our models. These ambiguities on Hep-2 production, however,
clearly exemplify that caution should be taken with respect to the
extrapolation of results obtained with one mouse strain to another.
A remarkable observation from our study concerned the
apparent absence of Hep-1 in urine and Hep-2 in serum.
Correspondingly, a recent proteomic analysis of urine from a
C57Bl/6 mouse model for glomerulonephritis also yielded the
detection of Hep-2, but not Hep-1 [9]. These findings can be
explained by the fact that Hep-1, in contrast to human Hepcidin-
25, may either not be filtrated by the kidney or is completely
degraded and/or reabsorbed by the tubule cells. As Hep-2 was not
detectable in serum and seemed unaffected by liver intoxication, it
is tempting to speculate that Hep-2 is for a substantial part
produced by the kidney or local inflammatory cells and processed
into urine. In fact, hepcidin expression has been shown in the renal
tubules and interstitial inflammatory cells of rats [16] and in
kidney biopsies of SLE patients [17]. Nevertheless, local Hep-2
production in the kidney and its potential physiological role
requires further investigation. It should be kept in mind, however,
that the peptide enrichment procedure in combination with the
different characteristics of serum and urine samples may for a
substantial part determine whether or not Hep-1 and/or Hep-2
are isolated, implicating that changes in this procedure or altering
matrix compositions may cause changes in their relative detection.
Another interesting observation concerned the fact that liver
iron, but not circulating iron levels, correlated significantly with
serum Hep-1 levels, thereby corroborating data on liver iron
induced local bone morphogenetic protein 6 (BMP6) levels as the
dominant regulator of hepatocyte hepcidin synthesis [18–20].
Moreover, serum Hep-1 levels appeared to be an excellent
determinant of spleen iron levels, fully consistent with the mode of
action of Hep-1, i.e. the sequestration of iron in the reticulo-
endothelial macrophages by internalisation and subsequent
degradation of the sole cellular iron exporter ferroportin [1,2,21].
In-line with previous studies showing that defects in the HFE and
TfR2 proteins (and their combination) upstream from hepcidin
synthesis resulted in low circulating hepcidin levels [22–27], our 3
mouse hemochromatosis models all showed impaired Hep-1
production, being most prominently present in double affected
Hfe/TfR2
y245x mice. This corroborates a concept in which lower
levels of bioactive hepcidin result in a clinically more severe
hemochromatosis [28,29]. Accordingly, the combined defect in
HFE and TfR2 in man has been shown to lead to more severe iron
loading and a juvenile form of hemochromatosis [30], suggesting
that these two genes have a least some hepcidin regulatory functions
that do not overlap. Furthermore, our findings are in agreement
with the reduced serum Hep-1 levels in mice homozygous and
heterozygous for targeted deletions in the hepcidin and HFE genes, as
measured by a hepcidin (ferroportin) binding assay [31,32].
Altogether, our study shows that mass spectrometry is a convenient
approach to monitor physiological relevant changes in hepcidin
peptide levels in experimental mouse models, which is essential to
provide new insights in post-transcriptional regulation, hepcidin
Figure 5. Serum Hep-1 levels and liver hepcidin-1 expression
obtained for mouse models of hereditary hemochromatosis
relative to wild-type (wt) mouse. Data are depicted as lower
quartile, median and upper quartile (boxes), and minimum and
maximum ranges (whiskers). Statistical analysis were performed using
ANOVA and Dunnett’s comparisons. Ns, not significantly different;
*, P,0.05; **, P,0.01; all compared to wild-type; a and b, significancy of
difference to homozygous Tfr2 mutated mice.
doi:10.1371/journal.pone.0016762.g005
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species variations in these levels, along with previously described
distinct hepcidin-1 and -2 expression patterns, may explain the
differences in iron homeostasis among mouse strains [33]. Impor-
tantly, the current study may facilitate the selection of a proper mouse
m o d e lt oa n s w e rap a r t i c u l a rr e s e a r c hq u e s t i o ni ni r o nm e t a b o l i s m .
Materials and Methods
Mass spectrometry
Surface Enhanced Laser Desorption Ionization (SELDI) Cu
2+
affinity-capture TOF MS was used for the routine detection of
mouse hepcidin peptides in urine and serum samples as previously
described for human samples [12,13]. Alternatively, mouse
hepcidin peptide enrichment was performed by a hydrophobic
interaction chromatography bead-based approach followed by
peptide profiling on a Matrix-assisted (MA)LDI-TOF MS
platform. The identity of Hep-1 in mouse serum was confirmed
by high resolution Matrix-Assisted Laser Desorption Ionization -
Fourier transform ion cyclotron resonance (MALDI-FTICR) MS
and that of Hep-2 by Q-STARXL MS/MS (see Supporting
information Materials and Methods S1 for details).
Experimental mouse models
Mouse models for hemochromatosis (homozygous Hfe knock-
out mice (Hfe KO), homozygous Tfr2
y245x mutated mice
(Tfr2
y245x) and double affected mice (Hfe/TfR2
y245x), dietary iron
challenge, infection (LPS challenge), and acute hepatotoxicity
following paracetamol administration were used to validate and
evaluate the utility of Hep-1/Hep-2 analysis by mass spectrometry
(see Supporting information for details). All animals received
human care and study protocols complied with the institutional
guidelines. Approval was obtained from the Animal Ethics
Committee of the Radboud University Nijmegen (RU-DEC
2008-142), the Austrian Federal Ministry of Science and Research
(BMWF-66.011/0111-II/10b/2008 and BMBWK-66.011/0080-
BrGT/2005), and the Institutional Animal Care and Use
Committee (IACUC) at Saint Louis University School of Medicine
(protocol # 1410). Male and female mice were randomly
distributed between the study groups.
Quantification of hepcidin mRNA
Liver hepcidin-1 mRNA was quantified by real-time RT-PCR
(ABI7700) using TaqMan reagents (Applied Biosystems; see
Supplemental information for primers and probes). Hepcidin-1
Figure 6. Serum and urine hepcidin levels upon stimulation by iron and LPS. Hep-1 in serum in Mega-intensities (Mint) per L (Mint/L) at
baseline (control, n=4) 24-hours after iron administration (n=4) and LPS stimulus (n=4). Hep-2 in urine in Mint/mmol creatinine (Cr) at baseline
(n=4) and 24-hours after iron (n=4) and LPS (n=4) stimulus. #, Hep-2 values in control and Fe group DBA/2 are .500 Mint/mmol Cr. Urine sample
restriction did not allow more precise measurements. Therefore, P-values for urine Hep-2 were not calculated for DBA/2 mice. C57Bl/6, open bars;
DBA/2, closed bars; BALB/c mice, dashed bars. Data are depicted as lower quartile, median and upper quartile (boxes), and minimum and maximum
ranges (whiskers). Differences of iron and LPS treated mouse from control within mouse strain are tested by Whitney tests; *, P,0.05. In this specific
experiment, hepcidin levels were measured in the absence of IS and therefore expressed in Mint/L for serum or/mmol Creatinine (Cr) for urine [12].
doi:10.1371/journal.pone.0016762.g006
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both the delta Ct method, and the previously described method
[34] using REST software (Qiagen).
Tissue iron concentrations
Liver and spleen non-heme iron concentrations were deter-
mined as described [35], and expressed as mg iron per g dry
weight.
Laboratory measurements
Urine creatinine was quantified by enzymatic detection. ALAT
levels were determined by NOTOX B.V. (‘s-Hertogenbosch, the
Netherlands). Serum IL-6 was determined as described previously
[36].
Supporting Information
Figure S1 Models of the mouse Hep-1 (A) and Hep-2 (B) protein
structures based on the known human hepcidin-25 structure (C).
For homology modeling, the human hepcidin structure (PDB file
3h0t), was used as input for the YASARA algorithm to swap the
human side chains for the corresponding side chains of mouse
Hep-1 and -2, respectively, including a standard energy minimi-
zation step. This resulting models for mouse Hep-1 and -2 showed
the same cysteine-bridge pattern as described for the human
hepcidin. Left side: Overview of the structures of the three
hepcidin distorted beta –sheets are shown as grey arrow, and the
peptide backbone is colored gray. The disulfide bonds are colored
yellow, positive residues of arginine (Arg) and lysine (Lys) are
picture in blue, the negative residue of asparctic acid (Asp) in red.
Right side: the molecule displayed with solvent accessible surface.
The molecule is colored gray, except for the side-chains of positive
(blue) and negative (red) residues. Mouse Hep-1; sequence:
DTNFPICIFCCKCCNNSQCGICCKT. Mass: 2754 Da; pI:
7.7. Mouse Hep-2; sequence: DINFPICRFCCQCCNKPSCGIC-
CEE. Mass: 2821 Da; pI: 4.9 Human hepcidin; sequence:
DTHFPICIFCCGCCHRSKCGMCCKT. Mass: 2789 Da; pI:
8.2.
(PDF)
Figure S2 Hep-1 contains 4 disulphide bridges. TOF MS profile
of a FVB mouse serum sample before (A) and after reduction with
DTT (B) and alkylation with IAA (C). Respective mass shifts of +8
Da and +456 Da specify the reduction of 4 disulfide bonds. Note
that a partial reaction resulted in an alkylation ladder (peaks
indicted with *) with size difference of 57 Da per moiety (from 5 to
8 modifications). Intensity is given in arbitrary units (AU).
(PDF)
Figure S3 Hep-2 contains 4 disulphide bridges. Hep-2 was
enriched by IMAC-Cu
2+ on-chip chemistry from urine of a
C57Bl6 mouse and analyzed by Q-STARXL MS before (A) and
after (B) reduction with DDT; upper spectrum shows reduced
Hep-2 (m/z 2828) and lower spectrum: native Hep-2 (m/z 2821).
Note that monoisotopic [M+H]
+ masses as measured by Q-
STARXL MS are about 1 Dalton lighter than the average masses
measured by TOF MS.
(PDF)
Figure S4 Hep-2 identification by Q-STARXL MS/MS. Hep-2
was enriched by IMAC-Cu2+ on-chip chemistry from urine of a
C57Bl6 mouse after which Q-STARXL MS/MS was used to
generate fragmentation spectra of the reduced m/z 2828 peptide
(A). Database search results for the MS/MS analysis of the m/z
2828 peptide are shown in panel B.
(PDF)
Figure S5 Identification of Hep-1 by MALDI-FTICR MS.
Serum Hep-1 from FVB mouse was enriched by IMAC-Cu
2+ on-
chip chemistry after which MALDI-FTICR MS was used for an
accurate mass measurement. The upper panel shows a part of the
resulting MALDI-FTICR spectrum. The peak of interest was
measured at m/z 2753.032 using external calibration. The mass
difference with the signal at m/z 2637.989 exactly corresponds to
an aspartic acid residue, which is only in agreement with a single
amino acid truncation at the N-terminus of Hep-1 (Table S1).
Additional evidence for the fact that the peptides at 2753 and 2637
have the same amino acid composition is found in their similar
isotopic distributions, shown in the enlarged parts of the lower
panel. In contrast, the peaks at m/z 2908 and 2791 also seem to be
related, but their mass difference of 117 does not correspond to
any amino acid residue. The exact mass difference between m/z
2908 and 2753 is 155.5, implying two different amino acid
compositions. Another indication that these two peptides are two
distinct structures is the different isotopic distributions of 2753 and
Figure 7. Hep-1 (upper panel) and IL-6 (lower panel) at baseline
(control, n=6), 2 hrs (n=6), 4 hrs (n=6) and 6 hrs (n=7) time
course after LPS injection in C57Bl/6 mice strain. IL-6 levels of
controlsare belowthedetection limit. Dataaredepicted as lower quartile,
median and upper quartile (boxes), and minimum and maximum ranges
(whiskers). Differences of serum hep-1 and IL-6 at 2 h, 4 h and 6 h
compared to controls are tested by Mann-Whitney test; **, P,0.01,
respectively.
doi:10.1371/journal.pone.0016762.g007
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Figure S6 Distinct urine and serum Hep-1 and Hep-2 forms in
diverse mouse strains. A, TOF MS serum profile of a FVB mouse,
B, serum profile of a DBA/2 mouse, Da. C, urine profile of FVB
mouse, D, urine profile of DBA/2 mouse. Note that DBA/2 mice
have, in contrast to other mouse strains, an Asn16Lys substitution
in mature Hep-1 resulting in a theoretical mass of 2768 Da and a
Ser18 Phe substitution; in mature Hep-2 resulting in a theoretical
mass of 2881 Da (see Figure S1). The measured mass shifts in Hep-
1/-2 in serum and urine from DBA/2, match with the altered
amino acid composition. Positions of Hep-1 and Hep-2 are
indicated. Peak intensity is given in arbitrary units (AU).
(PDF)
Figure S7 TOF MS profiles showing isoforms of Hep-2 in the
urine of A, a DBA/2 mouse (n=1), and B, C57Bl/6 mice (n=3).
Note that Hep-2 from DBA/2 mice has a deviant mass of 2881 Da
(instead of 2821 Da for other mouse strains) due to a Ser18 Phe
substitution in the mature part of Hep-2. The masses of the
indicated Hep-2 isoforms match to the theoretical masses of
amino-terminal truncated 23, 22 and 20 amino acid (aa) forms of
Hep-2. Panel B illustrates the inter-mouse heterogeneity in Hep-2
(isoform) levels in mouse urine. Intensity is given in arbitrary units
(AU).
(PDF)
Table S1
(PDF)
Materials and Methods S1
(PDF)
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